Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
camibirstat
- Development stage
- Phase 2
- Lead developer
- Foghorn Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**Camibirstat** (FHD-286) is an orally bioavailable small molecule that acts as a dual allosteric inhibitor of BRG1 (SMARCA4) and BRM (SMARCA2), the ATPase subunits of the BAF (BRG1/BRM-associated factor) chromatin remodeling complexes. By inhibiting these ATPases, it disrupts SWI/SNF-mediated chromatin remodeling and gene expression, downregulating oncogenic pathways and inhibiting tumor cell proliferation. Developed by Foghorn Therapeutics, it targets BAF-related cancers with SMARCA4/2 dependencies, such as acute myeloid leukemia (AML), and is under evaluation in Phase 1 trials, often in combinations like decitabine.[1][2][3][5]
- Other names
- camibirstat
02
Targets
SMARCA2 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin subfamily A member 2)SMARCA4 (SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A member 4)
Beyond the preview
Go deeper on camibirstat.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on camibirstat.